HealthcareMid capRs 15,795 crRs 25.3 cr traded a day
Close on 2026-08-21
882.40
+0.56%
52-week range22% of the way up
792.951,206.00
Market cap
15,795 cr
P/E (TTM)
13.8×
industry 44×
EPS (TTM)
63.95
Revenue YoY
-44.7%
Q1 FY27
Profit YoY
-57.0%
Net margin
28.1%
-8.1pt vs a year ago
Growth trend
-5.2pt
vs last quarter’s YoY
1 month
-3.9%
Below 52w high
36.7%
RSI (14)
36
Daily swing
3.1%
average true range
Volume
0.8×
vs 20-day average
Traded
Rs 25 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
−2.30%
1 month
−3.94%
3 months
−25.60%
6 months
−9.23%
1 year
+1.93%
The read
written from the numbers on this page
The evidence is mixed3 supporting, 3 against, 0 worth knowing
Supporting
up 2% over twelve months
matches long tail above — rejected higher, which has beaten the market by +0.39 points over 20 sessions across 16,308 past signals
priced at 14× earnings against an industry median of 44× — 69% below its peers
Against
trading 7% below its 200-day average
revenue fell 45% year on year in the quarter ending 2026-06-30
net margin has narrowed from 38.0% to 28.1% across four quarters
Worth knowing
nothing the data supports either way
What would change this read: a close back above 953, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
How it has performed
price return over each window, measured against zero
What the scans say today
1 of 47 matched on 2026-08-21
NATCOPHARM matches 1 of the 47 scans today, across 1 different kinds of evidence.
NATCOPHARM trades at 14× trailing earnings, above its median of 11× over this window — 29% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093) · Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352) · Results filings were typically -0.52pt vs the market over the next 5 sessions (n=7,520)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
nothing clear in the filed numbers
Going against it
revenue fell 45% against the same quarter a year earlier
profit dropped 57% year on year
net margin narrowed from 36.4% to 28.1%
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
735
186
206
11.53
28.1%
Q4 FY26
2026-03-31 · consolidated
739
144
269
14.96
36.4%
Q3 FY26
2025-12-31 · consolidated
647
161
151
8.46
23.4%
Q2 FY26
2025-09-30 · consolidated
1,363
614
518
28.94
38.0%
Q1 FY26
2025-06-30 · consolidated
1,329
572
480
26.84
36.1%
Q4 FY25
2025-03-31 · consolidated
1,221
506
406
22.70
33.3%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-4.2%
Versus 200-day average-7.4%
Below 52-week high-26.8%
Above 52-week low+11.3%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)36.5
Higher closes in last 52 of 5
Six-month return−9.23%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.06%
Volume versus 20-day0.8x
Median daily turnoverRs 25.3 cr
Peers
Healthcare · 67 classified companies
NATCOPHARM trades at 13.8× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — cheaper than them, by 69%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.